Pancreatic Cancer Research

ResearcherFred Hutch Cancer CenterActive in the last 2 years

Teresa A. Brentnall

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-8758-5475; OpenAlex author ID A5043802158; NIH RePORTER profile ID 6660557. Sources: OpenAlex.

Their work

Papers
35 (first author 5, last author 7)
Trials
0
Grants
1
Labs led
1
Collaborators
121
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers, 1 grant · 2013: 7 papers · 2014: 1 paper · 2015: 5 papers · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 35

  1. Development of a multiplex assay for early detection of pancreatic cancer in high-risk groups. Co-author DOI 10.1186/s12885-026-16058-3↗
  2. Familial pancreatic cancer: a long fruitful journey. Co-author DOI 10.1007/s10689-024-00364-5↗
  3. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  4. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  5. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  6. Proteomes of Extracellular Vesicles From Pancreatic Cancer Cells and Cancer-Associated Fibroblasts. Last author DOI 10.1097/mpa.0000000000002115↗
  7. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.biochi.2020.11.018↗
  8. Recommendations for a More Organized and Effective Approach to the Early Detection of Pancreatic Cancer From the PRECEDE (Pancreatic Cancer Early Detection) Co… Co-author DOI 10.1053/j.gastro.2021.08.036↗
  9. Proteome alterations in pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.canlet.2019.11.020↗
  10. Systemic Proteome Alterations Linked to Early Stage Pancreatic Cancer in Diabetic Patients. Co-author DOI 10.3390/cancers12061534↗
  11. Predictive proteomic signatures for response of pancreatic cancer patients receiving chemotherapy. Co-author DOI 10.1186/s12014-019-9251-3↗
  12. Spectral library-based glycopeptide analysis-detection of circulating galectin-3 binding protein in pancreatic cancer. Co-author DOI 10.1002/prca.201700064↗
  13. Disrupting glutamine metabolic pathways to sensitize gemcitabine-resistant pancreatic cancer. Co-author DOI 10.1038/s41598-017-08436-6↗
  14. Pancreatic Cancer Chemoprevention Translational Workshop: Meeting Report. Co-author DOI 10.1097/mpa.0000000000000705↗
  15. Progress in the Earlier Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.2016.66.5265↗
  16. Glycoproteins and glycoproteomics in pancreatic cancer. First author DOI 10.3748/wjg.v22.i42.9288↗
  17. Proteomics analysis of bodily fluids in pancreatic cancer. First author DOI 10.1002/pmic.201400476↗
  18. Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1038/labinvest.2014.128↗
  19. Early detection of sporadic pancreatic cancer: summative review. Co-author DOI 10.1097/mpa.0000000000000368↗
  20. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: p… Co-author DOI 10.1148/radiol.14140568↗
  21. Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions. Co-author DOI 10.1148/radiol.2015141020↗
  22. Quantitative glycoproteomics analysis reveals changes in N-glycosylation level associated with pancreatic ductal adenocarcinoma. Last author DOI 10.1021/pr4010184↗
  23. Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges. First author DOI 10.1002/pmic.201200319↗
  24. Clinical importance of Familial Pancreatic Cancer Registry in Japan: a report from kick-off meeting at International Symposium on Pancreas Cancer 2012. Co-author DOI 10.1007/s00534-013-0611-5↗
  25. Screening and surgical outcomes of familial pancreatic cancer. First author DOI 10.1016/j.suc.2013.02.002↗
  26. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Co-author DOI 10.1053/j.gastro.2013.06.011↗
  27. Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer. Co-author DOI 10.1073/pnas.1309720110↗
  28. Family history of diabetes and pancreatic cancer as risk factors for pancreatic cancer: the PACIFIC study. Co-author DOI 10.1158/1055-9965.epi-13-0518↗
  29. Molecular analysis of precursor lesions in familial pancreatic cancer. Last author DOI 10.1371/journal.pone.0054830↗
  30. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. Last author DOI 10.1021/pr201117w↗
  31. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Last author DOI 10.4161/cbt.20842↗
  32. Protein alterations associated with pancreatic cancer and chronic pancreatitis found in human plasma using global quantitative proteomics profiling. Last author DOI 10.1021/pr101148r↗
  33. Pancreatic cancer surveillance: learning as we go. Co-author DOI 10.1038/ajg.2011.68↗
  34. Characterization of alternative spliceoforms and the RNA splicing machinery in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31820128d2↗
  35. AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Co-author DOI 10.1158/0008-5472.can-11-1367↗

Grants 1

  1. Aberrant Glycosylation Signature in Pancreatic Cancer R21CA149772↗

Closest collaborators

The 25 strongest of 121 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ru Chen · 19 shared papers, 2011–2026 · strength 1.74
  2. Sheng Pan · 15 shared papers, 1 shared grant, 2011–2021 · strength 1.27
  3. Randall E. Brand · 7 shared papers, 2012–2026 · strength 0.85
  4. Diane M. Simeone · 7 shared papers, 2015–2024 · strength 0.62
  5. David W. Dawson · 3 shared papers, 2015–2022 · strength 0.35
  6. Sheng Pan · 1 shared paper, 2026 · strength 0.33
  7. Jessica N. Everett · 3 shared papers, 2021–2024 · strength 0.33
  8. Aaron J. Grossberg · 3 shared papers, 2021–2024 · strength 0.33
  9. James M. Lindberg · 3 shared papers, 2021–2024 · strength 0.33
  10. Bryson W. Katona · 3 shared papers, 2021–2024 · strength 0.33
  11. Kasmintan A. Schrader · 3 shared papers, 2021–2024 · strength 0.33
  12. Andrew M. Lowy · 3 shared papers, 2021–2024 · strength 0.33
  13. Sonia S. Kupfer · 3 shared papers, 2021–2024 · strength 0.33
  14. Aimee Lee Lucas · 3 shared papers, 2021–2024 · strength 0.33
  15. Salvatore Paiella · 3 shared papers, 2021–2024 · strength 0.33
  16. Daniel C. Chung · 3 shared papers, 2021–2024 · strength 0.33
  17. Yan Bi · 3 shared papers, 2021–2024 · strength 0.33
  18. George Zogopoulos · 3 shared papers, 2021–2024 · strength 0.33
  19. Jennifer B. Permuth · 3 shared papers, 2021–2024 · strength 0.33
  20. Fay Kastrinos · 3 shared papers, 2021–2024 · strength 0.33
  21. Yuanqing Yan · 2 shared papers, 2020–2022 · strength 0.27
  22. Raymond Couric Wadlow · 2 shared papers, 2023–2024 · strength 0.25
  23. James J. Farrell · 2 shared papers, 2023–2024 · strength 0.25
  24. Elena M. Stoffel · 2 shared papers, 2023–2024 · strength 0.25
  25. Julie Earl · 2 shared papers, 2023–2024 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.